Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
above,26898299,C min,"For patients with amatuximab C min above the median (38.2 μg/mL), the median OS was 583 days (90 % CI 418 -NE).","Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898299/),[μg] / [ml],38.2,3992,DB00642,Pemetrexed
,26898299,OS,"For patients with amatuximab C min above the median (38.2 μg/mL), the median OS was 583 days (90 % CI 418 -NE).","Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898299/),d,583,3993,DB00642,Pemetrexed
≤,26898299,C min,"For patients with C min ≤ 38.2 μg/mL, the median OS was 375 days (90 % CI 325-486).","Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898299/),[μg] / [ml],38.2,3994,DB00642,Pemetrexed
,26898299,OS,"For patients with C min ≤ 38.2 μg/mL, the median OS was 375 days (90 % CI 325-486).","Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898299/),d,375,3995,DB00642,Pemetrexed
,22927839,survival,The median survival for all 10 patients was 33.5 months.,Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous Cisplatin for diffuse malignant peritoneal mesothelioma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22927839/),month,33.5,5840,DB00642,Pemetrexed
,22927839,peritoneal to plasma area under the curve ratio,Pharmacokinetic analysis of intraperitoneal pemetrexed showed a peritoneal to plasma area under the curve ratio of 70.,Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous Cisplatin for diffuse malignant peritoneal mesothelioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22927839/),,70,5841,DB00642,Pemetrexed
,21989766,MTD,"In patients with advanced solid malignancies, the MTD of sunitinib plus 500 mg/m(2) pemetrexed was 37.5 mg/day (CDD schedule) or 50 mg/day (Schedule 2/1).","A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21989766/),mg,37.,12691,DB00642,Pemetrexed
,24688087,area under the concentration-time curve,Patients received escalated doses of carboplatin at an area under the concentration-time curve of 4 (Level 1) or 5 (Level 2) plus pemetrexed (500 mg/m(2)) every 3 weeks for a maximum of six cycles.,Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688087/),,4,15758,DB00642,Pemetrexed
,24688087,area under the concentration-time curve,Patients received escalated doses of carboplatin at an area under the concentration-time curve of 4 (Level 1) or 5 (Level 2) plus pemetrexed (500 mg/m(2)) every 3 weeks for a maximum of six cycles.,Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688087/),,5,15759,DB00642,Pemetrexed
,24688087,area under the concentration-time curve,"No dose-limiting toxicities were observed in patients at Level 1 or the first six patients at Level 2, and therefore the combination of carboplatin at an area under the concentration-time curve of 5 plus pemetrexed at 500 mg/m(2) was considered to be the recommended dose.",Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688087/),,5,15760,DB00642,Pemetrexed
,24688087,overall response rate,"Six patients showed partial responses, giving the overall response rate of 30%.",Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688087/),%,30,15761,DB00642,Pemetrexed
,24688087,progression-free survival period,The median progression-free survival period was 4.8 months (95% confidence interval 2.9-6.7 months).,Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688087/),month,4.8,15762,DB00642,Pemetrexed
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,6.28,17149,DB00642,Pemetrexed
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,9.63,17150,DB00642,Pemetrexed
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,3.15,17151,DB00642,Pemetrexed
,15987831,area under concentration-time curve (AUC)(brain)/AUC(plasma) ratio,The mean area under concentration-time curve (AUC)(brain)/AUC(plasma) ratio of unbound pemetrexed was 0.078 +/- 0.038 in the i.v. bolus study.,Distribution of the novel antifolate pemetrexed to the brain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987831/),,0.078,22824,DB00642,Pemetrexed
,15987831,steady-state brain-to-plasma unbound concentration ratio,The pemetrexed steady-state brain-to-plasma unbound concentration ratio after i.v. infusion was 0.106 +/- 0.054.,Distribution of the novel antifolate pemetrexed to the brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987831/),,0.106,22825,DB00642,Pemetrexed
,26560486,MTD,The MTD of nintedanib plus pemetrexed was 200 mg bid.,Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26560486/),mg,200,23208,DB00642,Pemetrexed
,26560486,MTD,"As in Caucasian patients, the MTD of nintedanib was 200 mg bid.",Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26560486/),mg,200,23209,DB00642,Pemetrexed
,26403509,MTD,MTD of LY with pemetrexed/carboplatin was 40 mg.,"A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26403509/),mg,40,27239,DB00642,Pemetrexed
,9533527,maximum tolerated dose,"A maximum tolerated dose of 4.0 mg/m2/day was determined, with neutropenia as the predominant dose-limiting toxicity.","A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533527/),[mg] / [d·m2],4.0,30361,DB00642,Pemetrexed
,9533527,total body clearance,"The drug was cleared with a day 1 total body clearance of 108.9 +/- 38.8 ml/min/m2, with plasma concentrations declining with a mean harmonic terminal half-life of 1.4 +/- 0.98 h.","A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533527/),[ml] / [m2·min],108.9,30362,DB00642,Pemetrexed
,9533527,terminal half-life,"The drug was cleared with a day 1 total body clearance of 108.9 +/- 38.8 ml/min/m2, with plasma concentrations declining with a mean harmonic terminal half-life of 1.4 +/- 0.98 h.","A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533527/),h,1.4,30363,DB00642,Pemetrexed
,30317534,Response rate,Response rate was 37.5% for cohort 1 and 30.4% for cohort 2.,Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30317534/),%,37.5,31239,DB00642,Pemetrexed
,30317534,Response rate,Response rate was 37.5% for cohort 1 and 30.4% for cohort 2.,Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30317534/),%,30.4,31240,DB00642,Pemetrexed
,30082474,disease control rate,"The disease control rate was 57% for patients treated with abemaciclib-pemetrexed, 25% for abemaciclib-gemcitabine, and 54% for abemaciclib-ramucirumab.",Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082474/),%,57,31844,DB00642,Pemetrexed
,30082474,disease control rate,"The disease control rate was 57% for patients treated with abemaciclib-pemetrexed, 25% for abemaciclib-gemcitabine, and 54% for abemaciclib-ramucirumab.",Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082474/),%,25,31845,DB00642,Pemetrexed
,30082474,disease control rate,"The disease control rate was 57% for patients treated with abemaciclib-pemetrexed, 25% for abemaciclib-gemcitabine, and 54% for abemaciclib-ramucirumab.",Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082474/),%,54,31846,DB00642,Pemetrexed
,30082474,progression-free survival,"Median progression-free survival was 5.55, 1.58, and 4.83 months, respectively.",Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082474/),month,5.55,31847,DB00642,Pemetrexed
,30082474,progression-free survival,"Median progression-free survival was 5.55, 1.58, and 4.83 months, respectively.",Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082474/),month,1.58,31848,DB00642,Pemetrexed
,30082474,progression-free survival,"Median progression-free survival was 5.55, 1.58, and 4.83 months, respectively.",Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082474/),month,4.83,31849,DB00642,Pemetrexed
,9193870,AUC,"Doses (iv) of the compound showed high plasma levels, resulting in AUC values of 30-33 micrograms-hr/ml for mice and dogs after 20 and 7.5 mg/kg doses, respectively.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),[μgrams-hr] / [ml],30-33,35734,DB00642,Pemetrexed
,9193870,Half-life,"Half-life values for mice and dogs were about 7 and 2 hr, respectively.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),h,7,35735,DB00642,Pemetrexed
,9193870,Half-life,"Half-life values for mice and dogs were about 7 and 2 hr, respectively.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),h,2,35736,DB00642,Pemetrexed
,9193870,plasma binding,"In vitro plasma binding measured 56% in mice, 46% in dogs, and 81% in humans.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),%,56,35737,DB00642,Pemetrexed
,9193870,plasma binding,"In vitro plasma binding measured 56% in mice, 46% in dogs, and 81% in humans.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),%,46,35738,DB00642,Pemetrexed
,9193870,plasma binding,"In vitro plasma binding measured 56% in mice, 46% in dogs, and 81% in humans.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),%,81,35739,DB00642,Pemetrexed
,18269776,time to progression,"Median time to progression was 5.3 months (95% CI, 3.1-8.9 months), and median time to treatment failure was 3.5 months (95% CI, 2.6-5.9 months).",Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18269776/),month,5.3,37883,DB00642,Pemetrexed
,18269776,time to treatment failure,"Median time to progression was 5.3 months (95% CI, 3.1-8.9 months), and median time to treatment failure was 3.5 months (95% CI, 2.6-5.9 months).",Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18269776/),month,3.5,37884,DB00642,Pemetrexed
,19509274,maximum inhibition,"However, maximum inhibition of thymidine incorporation into tumors was only 50%, which was insufficient to enhance pemetrexed antitumor activity in vivo.",Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19509274/),%,50,43494,DB00642,Pemetrexed
exceeded,23054206,MTD,The MTD was exceeded at 100 mg/m(2)/d due to grade 3 anemia in 50 % of patients.,"A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23054206/),,100,46603,DB00642,Pemetrexed
,23054206,t1/2,TRC102 exposure increased in proportion to dose with a mean t1/2 of 28 h.,"A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23054206/),h,28,46604,DB00642,Pemetrexed
,23136232,area under the concentration-time curve (AUC),"The combination of carboplatin at an area under the concentration-time curve (AUC) of 5, and 500 mg/m(2) pemetrexed, was determined to be the recommended dose for elderly patients with advanced nonsquamous NSCLC.",Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136232/),,5,59900,DB00642,Pemetrexed
,23136232,overall response rate,The study had an overall response rate of 47.1%.,Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136232/),%,47.1,59901,DB00642,Pemetrexed
,23136232,progression-free survival time,The median progression-free survival time was 142 days (95% confidence interval [CI] 68-216 days) and the median overall survival time was 461 days (95% CI 168-754 days).,Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136232/),d,142,59902,DB00642,Pemetrexed
,23136232,overall survival time,The median progression-free survival time was 142 days (95% confidence interval [CI] 68-216 days) and the median overall survival time was 461 days (95% CI 168-754 days).,Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136232/),d,461,59903,DB00642,Pemetrexed
,23136232,area under the curve (AUC),"This combination was a tolerable and effective regimen, and recommended dose (RD) was carboplatin [area under the curve (AUC) of 5]/pemetrexed (500 mg/m(2)) every 3 weeks, in chemotherapy-naïve, elderly (≥75 years old) patients with advanced nonsquamous NSCLC.",Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136232/),,5,59904,DB00642,Pemetrexed
,25260366,lead-in time,Prior supplementation with folic acid and vitamin B12 is required to reduce pemetrexed therapy toxicity; the recommended lead-in time is at least 7 days.,A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260366/),,7,67200,DB00642,Pemetrexed
,25260366,response rate,The response rate to chemotherapy was 43%.,A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260366/),%,43,67201,DB00642,Pemetrexed
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.25,67452,DB00642,Pemetrexed
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.27,67453,DB00642,Pemetrexed
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.31,67454,DB00642,Pemetrexed
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.26,67455,DB00642,Pemetrexed
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.37,67456,DB00642,Pemetrexed
,11448930,peak plasma concentrations,"i.p. administration of 10 mg/kg NU3108, NU3121, and DP produced peak plasma concentrations of 4.4, 2.1, and 6.7 microM, respectively, and levels were sustained above 1 microM for approximately 45 min (DP) and 120 min (NU3108 and NU3121).",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,4.4,67457,DB00642,Pemetrexed
,11448930,peak plasma concentrations,"i.p. administration of 10 mg/kg NU3108, NU3121, and DP produced peak plasma concentrations of 4.4, 2.1, and 6.7 microM, respectively, and levels were sustained above 1 microM for approximately 45 min (DP) and 120 min (NU3108 and NU3121).",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,2.1,67458,DB00642,Pemetrexed
,11448930,peak plasma concentrations,"i.p. administration of 10 mg/kg NU3108, NU3121, and DP produced peak plasma concentrations of 4.4, 2.1, and 6.7 microM, respectively, and levels were sustained above 1 microM for approximately 45 min (DP) and 120 min (NU3108 and NU3121).",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,6.7,67459,DB00642,Pemetrexed
,18956139,MTD,"MTD was 500/135 mg/m(2) (S1), 400/40 mg/m(2) (S2), and 500/120 mg/m(2) (S3).",Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956139/),mg,500,91617,DB00642,Pemetrexed
,18956139,MTD,"MTD was 500/135 mg/m(2) (S1), 400/40 mg/m(2) (S2), and 500/120 mg/m(2) (S3).",Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956139/),mg,135,91618,DB00642,Pemetrexed
,26003007,progression-free survival,"Five of 9 (56%) patients had a partial response and the median progression-free survival was 7 months (range, 1.5-15.1 months).","Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26003007/),month,7,95368,DB00642,Pemetrexed
,26003007,progression-free survival,"Five of 9 (56%) patients had a partial response and the median progression-free survival was 7 months (range, 1.5-15.1 months).","Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26003007/),month,7,95369,DB00642,Pemetrexed
,30885337,area under the concentration-time curve (AUC),The pharmacokinetic target was an area under the concentration-time curve (AUC) of 123-205 mg·h/L.,Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30885337/),[h·mg] / [l],123-205,96592,DB00642,Pemetrexed
,30885337,systemic clearance,"Interestingly, a threefold increase in systemic clearance of pemetrexed was observed during hemodialysis (from 1.00 L/h to 3.01 L/h), which approximates the population clearance of pemetrexed.",Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30885337/),[l] / [h],1.00,96593,DB00642,Pemetrexed
,30885337,systemic clearance,"Interestingly, a threefold increase in systemic clearance of pemetrexed was observed during hemodialysis (from 1.00 L/h to 3.01 L/h), which approximates the population clearance of pemetrexed.",Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30885337/),[l] / [h],3.01,96594,DB00642,Pemetrexed
,31065954,MTD,The MTD was defined as 15 mg/kg and used for cohort expansion.,"A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31065954/),[mg] / [kg],15,102565,DB00642,Pemetrexed
,31544065,MTD,MTD was 10 mg.,A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31544065/),mg,10,104609,DB00642,Pemetrexed
,31446981,objective response rate,"Amongst patients treated at the MTD, the objective response rate was 14%.",Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31446981/),%,14,114372,DB00642,Pemetrexed
,31446981,MTD,"In patients with previously treated metastatic NSCLC, the MTD of luminespib in combination with pemetrexed was 55 mg/m2 per week.",Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31446981/),[mg] / [m2·week],55,114373,DB00642,Pemetrexed
,27350064,progression-free survival,"The median progression-free survival was 2.3 months (range, 0-27.1).","Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27350064/),month,2.3,118513,DB00642,Pemetrexed
,17255273,AUC,Regimen 1 was pemetrexed (200-600 mg/m(2)); regimen 2 was pemetrexed (500 mg/m(2)) with escalating carboplatin doses (AUC = 4-6).,"A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255273/),,4-6,123627,DB00642,Pemetrexed
,17255273,AUC,"In regimen 2, one dose-limiting toxicity (grade 3 esophagitis) occurred (500 mg/m(2); AUC = 6); grade 3/4 leukopenia (4 of 12 patients) was the main hematologic toxicity.","A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255273/),,6,123628,DB00642,Pemetrexed
,17255273,AUC,"When systemically active chemotherapy doses were reached, further dose escalation was discontinued, and a phase II dose-range was established (pemetrexed 500 mg/m(2) and carboplatin AUC = 5-6).","A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255273/),,5-6,123629,DB00642,Pemetrexed
,17255273,AUC,"The combination of pemetrexed (500 mg/m(2)) and carboplatin (AUC = 5 or 6) with concurrent radiation is well tolerated, allows for the administration of systemically active chemotherapy doses, and shows signs of activity.","A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255273/),,5,123630,DB00642,Pemetrexed
,17255273,AUC,"The combination of pemetrexed (500 mg/m(2)) and carboplatin (AUC = 5 or 6) with concurrent radiation is well tolerated, allows for the administration of systemically active chemotherapy doses, and shows signs of activity.","A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255273/),,6,123631,DB00642,Pemetrexed
,17145830,MTD,"The MTD of pemetrexed was 2,400 mg/m(2) (combined with cyclophosphamide, 600 mg/m(2)) with dose-limiting toxicities of grade 4 neutropenia with grade 4 infection and grade 3 diarrhea.",A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145830/),[mg] / [m],"2,400",126316,DB00642,Pemetrexed
,10760756,overall response rate,"Among 39 patients eligible for efficacy analysis, 1 complete response and 5 partial responses were identified, for an overall response rate of 15.4% (95% confidence interval [CI], 4.1-26. 7%) for all patients.","Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10760756/),%,15.4,129883,DB00642,Pemetrexed
,10760756,time to progression,"The median survival was 16.2 months (95% CI, 10.5-17.0%); 65% of patients were alive at 1 year, and the median time to progression was 4.4 months (range, 3.2-5.7 months).","Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10760756/),month,4.4,129884,DB00642,Pemetrexed
,7595747,half-life,"At the 40-mg/m2/wk dose level, the mean harmonic half-life, maximum plasma concentration, clearance, and apparent volume of distribution at steady-state were 2.02 hours, 11.20 micrograms/mL, 52.3 mL/min/m2, and 6.64 L/m2, respectively.","Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595747/),h,2.02,132183,DB00642,Pemetrexed
,7595747,maximum plasma concentration,"At the 40-mg/m2/wk dose level, the mean harmonic half-life, maximum plasma concentration, clearance, and apparent volume of distribution at steady-state were 2.02 hours, 11.20 micrograms/mL, 52.3 mL/min/m2, and 6.64 L/m2, respectively.","Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595747/),[μg] / [ml],11.20,132184,DB00642,Pemetrexed
,7595747,maximum plasma concentration,"At the 40-mg/m2/wk dose level, the mean harmonic half-life, maximum plasma concentration, clearance, and apparent volume of distribution at steady-state were 2.02 hours, 11.20 micrograms/mL, 52.3 mL/min/m2, and 6.64 L/m2, respectively.","Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595747/),[ml] / [m2·min],52.3,132185,DB00642,Pemetrexed
,7595747,clearance,"At the 40-mg/m2/wk dose level, the mean harmonic half-life, maximum plasma concentration, clearance, and apparent volume of distribution at steady-state were 2.02 hours, 11.20 micrograms/mL, 52.3 mL/min/m2, and 6.64 L/m2, respectively.","Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595747/),[μg] / [ml],11.20,132186,DB00642,Pemetrexed
,7595747,clearance,"At the 40-mg/m2/wk dose level, the mean harmonic half-life, maximum plasma concentration, clearance, and apparent volume of distribution at steady-state were 2.02 hours, 11.20 micrograms/mL, 52.3 mL/min/m2, and 6.64 L/m2, respectively.","Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595747/),[ml] / [m2·min],52.3,132187,DB00642,Pemetrexed
,7595747,apparent volume of distribution at steady-state,"At the 40-mg/m2/wk dose level, the mean harmonic half-life, maximum plasma concentration, clearance, and apparent volume of distribution at steady-state were 2.02 hours, 11.20 micrograms/mL, 52.3 mL/min/m2, and 6.64 L/m2, respectively.","Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595747/),[l] / [m2],6.64,132188,DB00642,Pemetrexed
,32039681,zeta potential,The nanocomposites were found to have a particle size of 121.9 ± 1.85 nm and zeta potential -12.1 ± 0.63 mV.,"The Development of Pemetrexed Diacid-Loaded Gelatin-Cloisite 30B (MMT) Nanocomposite for Improved Oral Efficacy Against Cancer: Characterization, In-Vitro and Ex-Vivo Assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32039681/),mv,12.1,134402,DB00642,Pemetrexed
,16940981,MTD/RD,"The MTD/RD were determined to be 1,200/1,000 mg m(-2), respectively.",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,200",151074,DB00642,Pemetrexed
,16940981,MTD/RD,"The MTD/RD were determined to be 1,200/1,000 mg m(-2), respectively.",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,000",151075,DB00642,Pemetrexed
,16940981,MTD/RD,"The MTD/RD of pemetrexed were determined to be 1,200/1,000 mg m(-2), respectively, that is, a higher RD than without FA/VB(12) (500 mg m(-2)).",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,200",151076,DB00642,Pemetrexed
,16940981,MTD/RD,"The MTD/RD of pemetrexed were determined to be 1,200/1,000 mg m(-2), respectively, that is, a higher RD than without FA/VB(12) (500 mg m(-2)).",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,000",151077,DB00642,Pemetrexed
,28371303,AUC0-inf,"Mean AUC0-inf for the generic and innovator formulations was 218.2 ± 19.18 and 223.6 ± 34.24 μg·h/mL, respectively, and mean Cmax was 119 ± 13.44 and 113 ± 7.26 μg/mL, respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),[h·μg] / [ml],218.2,157838,DB00642,Pemetrexed
,28371303,AUC0-inf,"Mean AUC0-inf for the generic and innovator formulations was 218.2 ± 19.18 and 223.6 ± 34.24 μg·h/mL, respectively, and mean Cmax was 119 ± 13.44 and 113 ± 7.26 μg/mL, respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),[h·μg] / [ml],223.6,157839,DB00642,Pemetrexed
,28371303,Cmax,"Mean AUC0-inf for the generic and innovator formulations was 218.2 ± 19.18 and 223.6 ± 34.24 μg·h/mL, respectively, and mean Cmax was 119 ± 13.44 and 113 ± 7.26 μg/mL, respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),[μg] / [ml],119,157840,DB00642,Pemetrexed
,28371303,Cmax,"Mean AUC0-inf for the generic and innovator formulations was 218.2 ± 19.18 and 223.6 ± 34.24 μg·h/mL, respectively, and mean Cmax was 119 ± 13.44 and 113 ± 7.26 μg/mL, respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),[μg] / [ml],113,157841,DB00642,Pemetrexed
,28371303,Volume of distribution,"Volume of distribution of pemetrexed was 17.5 and 27.6 L, clearance was 4.2 versus 4.72 L/h, and half-life was 4.3 and 4.83 h in the 2 arms respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),l,17.5,157842,DB00642,Pemetrexed
,28371303,Volume of distribution,"Volume of distribution of pemetrexed was 17.5 and 27.6 L, clearance was 4.2 versus 4.72 L/h, and half-life was 4.3 and 4.83 h in the 2 arms respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),l,27.6,157843,DB00642,Pemetrexed
,28371303,clearance,"Volume of distribution of pemetrexed was 17.5 and 27.6 L, clearance was 4.2 versus 4.72 L/h, and half-life was 4.3 and 4.83 h in the 2 arms respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),[l] / [h],4.2,157844,DB00642,Pemetrexed
,28371303,clearance,"Volume of distribution of pemetrexed was 17.5 and 27.6 L, clearance was 4.2 versus 4.72 L/h, and half-life was 4.3 and 4.83 h in the 2 arms respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),[l] / [h],4.72,157845,DB00642,Pemetrexed
,28371303,half-life,"Volume of distribution of pemetrexed was 17.5 and 27.6 L, clearance was 4.2 versus 4.72 L/h, and half-life was 4.3 and 4.83 h in the 2 arms respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),h,4.3,157846,DB00642,Pemetrexed
,28371303,half-life,"Volume of distribution of pemetrexed was 17.5 and 27.6 L, clearance was 4.2 versus 4.72 L/h, and half-life was 4.3 and 4.83 h in the 2 arms respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),h,4.83,157847,DB00642,Pemetrexed
,28371303,objective response,"Both formulations showed comparable response rates (objective response of 45% versus 50% in the Pemgem and Alimta arms, respectively) and similar safety profiles.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),,45,157848,DB00642,Pemetrexed
,28371303,objective response,"Both formulations showed comparable response rates (objective response of 45% versus 50% in the Pemgem and Alimta arms, respectively) and similar safety profiles.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),,50,157849,DB00642,Pemetrexed
,17442992,MTD,"The MTD was 1,910 mg/m2.",Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442992/),[mg] / [m2],"1,910",172410,DB00642,Pemetrexed
,17442992,plasma clearance,"Mean plasma clearance, half-life, and steady-state volume of distribution values were 2.3 L/h/m2, 2.5 hours, and 5.4 L/m2, respectively.",Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442992/),[l] / [h·m2],2.3,172411,DB00642,Pemetrexed
,17442992,half-life,"Mean plasma clearance, half-life, and steady-state volume of distribution values were 2.3 L/h/m2, 2.5 hours, and 5.4 L/m2, respectively.",Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442992/),h,2.5,172412,DB00642,Pemetrexed
,17442992,steady-state volume of distribution,"Mean plasma clearance, half-life, and steady-state volume of distribution values were 2.3 L/h/m2, 2.5 hours, and 5.4 L/m2, respectively.",Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442992/),[l] / [m2],5.4,172413,DB00642,Pemetrexed
,23108697,relative dose intensity,"Cumulative myelosuppression was problematic: the median relative dose intensity (% actual/intended) across all cycles was 61 % for sunitinib, 78 % for pemetrexed, and 74 % for cisplatin.","Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108697/),,61,180535,DB00642,Pemetrexed
,23108697,relative dose intensity,"Cumulative myelosuppression was problematic: the median relative dose intensity (% actual/intended) across all cycles was 61 % for sunitinib, 78 % for pemetrexed, and 74 % for cisplatin.","Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108697/),,78,180536,DB00642,Pemetrexed
,24934863,elimination half-life (t ½ elimination),The plasma PEM pharmacokinetics calculated showed an elimination half-life (t ½ elimination) of 3.2 h and distribution half-life (t ½-distribution) of 6 min.,Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),h,3.2,180591,DB00642,Pemetrexed
,24934863,distribution half-life (t ½-distribution),The plasma PEM pharmacokinetics calculated showed an elimination half-life (t ½ elimination) of 3.2 h and distribution half-life (t ½-distribution) of 6 min.,Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),min,6,180592,DB00642,Pemetrexed
,24934863,Clearance (CL),"Clearance (CL) was 5.1 L/h, central volume of distribution (V(central)) 23.2 L and peripheral volume distribution (V(peripheral)) 10.6 L, and the area under the curve was 186 μg h/mL.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),[l] / [h],5.1,180593,DB00642,Pemetrexed
,24934863,central volume of distribution (V(central)),"Clearance (CL) was 5.1 L/h, central volume of distribution (V(central)) 23.2 L and peripheral volume distribution (V(peripheral)) 10.6 L, and the area under the curve was 186 μg h/mL.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),l,23.2,180594,DB00642,Pemetrexed
,24934863,peripheral volume distribution (V(peripheral)),"Clearance (CL) was 5.1 L/h, central volume of distribution (V(central)) 23.2 L and peripheral volume distribution (V(peripheral)) 10.6 L, and the area under the curve was 186 μg h/mL.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),l,10.6,180595,DB00642,Pemetrexed
,24934863,area under the curve,"Clearance (CL) was 5.1 L/h, central volume of distribution (V(central)) 23.2 L and peripheral volume distribution (V(peripheral)) 10.6 L, and the area under the curve was 186 μg h/mL.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),[h·μg] / [ml],186,180596,DB00642,Pemetrexed
,24934863,elimination half-life,"Using non-compartment methods, an elimination half-life of 3.1 h and an apparent CL of 3.2 L/h were measured, whereas an apparent steady-state volume became 14.2 L.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),h,3.1,180597,DB00642,Pemetrexed
,24934863,apparent CL,"Using non-compartment methods, an elimination half-life of 3.1 h and an apparent CL of 3.2 L/h were measured, whereas an apparent steady-state volume became 14.2 L.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),[l] / [h],3.2,180598,DB00642,Pemetrexed
,24934863,apparent steady-state volume,"Using non-compartment methods, an elimination half-life of 3.1 h and an apparent CL of 3.2 L/h were measured, whereas an apparent steady-state volume became 14.2 L.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),l,14.2,180599,DB00642,Pemetrexed
,24934863,elimination half-life,"The pleura concentrations were only half of simultaneous plasma concentrations, and elimination half-life was 3.15 h.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),h,3.15,180600,DB00642,Pemetrexed
,12177114,area under the plasma concentration-time curve (AUC),"Doses ranged from pemetrexed 400 mg/m(2) (as a 10-minute intravenous infusion), followed by carboplatin area under the plasma concentration-time curve (AUC) 4 mg/mL.min (as a 30-minute intravenous infusion) to pemetrexed 500 mg/m(2), carboplatin AUC 6 mg/mL.min.",Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),[mg] / [min·ml],4,181201,DB00642,Pemetrexed
,12177114,AUC,"Doses ranged from pemetrexed 400 mg/m(2) (as a 10-minute intravenous infusion), followed by carboplatin area under the plasma concentration-time curve (AUC) 4 mg/mL.min (as a 30-minute intravenous infusion) to pemetrexed 500 mg/m(2), carboplatin AUC 6 mg/mL.min.",Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),[mg] / [min·ml],6,181202,DB00642,Pemetrexed
,12177114,response rate,Eight partial responses (in 25 assessable patients) were observed for a response rate of 32%.,Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),%,32,181203,DB00642,Pemetrexed
,12177114,time to progression,"Median time to progression was 305 days, and median survival time was 451 days.",Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),d,305,181204,DB00642,Pemetrexed
,12177114,survival time,"Median time to progression was 305 days, and median survival time was 451 days.",Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),d,451,181205,DB00642,Pemetrexed
,12177114,AUC,The MTD was pemetrexed 500 mg/m(2) and carboplatin AUC 6 mg/mL.min.,Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),[mg] / [min·ml],6,181206,DB00642,Pemetrexed
,12177114,AUC,The recommended phase II dose of the combination is pemetrexed 500 mg/m(2) and carboplatin AUC 5 mg/mL.min.,Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),[mg] / [min·ml],5,181207,DB00642,Pemetrexed
,27473308,zeta potential,Particles size was below 100nm in diameter and zeta potential ranged - (25-30).,Modified-chitosan nanoparticles: Novel drug delivery systems improve oral bioavailability of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473308/),,25-30,206887,DB00642,Pemetrexed
,19247087,C(max),The C(max) was significantly lower after intrapleural versus intravenous administration of 10 mg/kg pemetrexed (14.36 microg/ml versus 29.83 microg/ml; p = 0.008) or 100 mg/kg pemetrexed (70.64 microg/ml versus 218.64 microg/ml; p = 0.001).,Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19247087/),[μg] / [ml],14.36,208888,DB00642,Pemetrexed
,19247087,C(max),The C(max) was significantly lower after intrapleural versus intravenous administration of 10 mg/kg pemetrexed (14.36 microg/ml versus 29.83 microg/ml; p = 0.008) or 100 mg/kg pemetrexed (70.64 microg/ml versus 218.64 microg/ml; p = 0.001).,Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19247087/),[μg] / [ml],29.83,208889,DB00642,Pemetrexed
,19247087,C(max),The C(max) was significantly lower after intrapleural versus intravenous administration of 10 mg/kg pemetrexed (14.36 microg/ml versus 29.83 microg/ml; p = 0.008) or 100 mg/kg pemetrexed (70.64 microg/ml versus 218.64 microg/ml; p = 0.001).,Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19247087/),[μg] / [ml],70.64,208890,DB00642,Pemetrexed
,19247087,C(max),The C(max) was significantly lower after intrapleural versus intravenous administration of 10 mg/kg pemetrexed (14.36 microg/ml versus 29.83 microg/ml; p = 0.008) or 100 mg/kg pemetrexed (70.64 microg/ml versus 218.64 microg/ml; p = 0.001).,Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19247087/),[μg] / [ml],218.64,208891,DB00642,Pemetrexed
,31561135,AUC1,"Patients with severe chemotherapy-related AEs (n = 55) had significantly higher AUC1 values than patients without them (n = 51) (226 ± 53 vs 190 ± 31, p < 0.001).",Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31561135/),,226,209616,DB00642,Pemetrexed
,31561135,AUC1,"Patients with severe chemotherapy-related AEs (n = 55) had significantly higher AUC1 values than patients without them (n = 51) (226 ± 53 vs 190 ± 31, p < 0.001).",Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31561135/),,190,209617,DB00642,Pemetrexed
,11078617,area under the curve (AUC),When MTA was delivered at 10 mg/kg the area under the curve (AUC) of the peritoneal fluid was significantly higher with intraperitoneal administration (10 778 microg/mlxmin) compared to intravenous administration (454 microg/mlxmin) (P<0.0001).,Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11078617/),[μg] / [min·ml],10 778,212451,DB00642,Pemetrexed
,11078617,area under the curve (AUC),When MTA was delivered at 10 mg/kg the area under the curve (AUC) of the peritoneal fluid was significantly higher with intraperitoneal administration (10 778 microg/mlxmin) compared to intravenous administration (454 microg/mlxmin) (P<0.0001).,Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11078617/),[μg] / [min·ml],454,212452,DB00642,Pemetrexed
,11078617,AUC ratio (AUC peritoneal fluid/AUC plasma),The AUC ratio (AUC peritoneal fluid/AUC plasma) was 40.8 for intraperitoneal delivery as opposed to 0.014 for intravenous delivery (P=0.0063).,Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11078617/),,40.8,212453,DB00642,Pemetrexed
,11078617,AUC ratio (AUC peritoneal fluid/AUC plasma),The AUC ratio (AUC peritoneal fluid/AUC plasma) was 40.8 for intraperitoneal delivery as opposed to 0.014 for intravenous delivery (P=0.0063).,Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11078617/),,0.014,212454,DB00642,Pemetrexed
,11078617,AUC ratio,The AUC ratio for intraperitoneal MTA at 100 mg/kg was 19.2.,Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11078617/),,19.2,212455,DB00642,Pemetrexed
,11078617,half-life,The half-life of MTA in the peritoneal fluid after intraperitoneal infusion was approximately 2 hours.,Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11078617/),h,2,212456,DB00642,Pemetrexed
,22492020,maximum tolerated dose,The maximum tolerated dose was defined as 150 mg/m(2).,"Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22492020/),[mg] / [m],150,216549,DB00642,Pemetrexed
,16855840,distribution half-life,Pemetrexed disappearance from plasma was best described by a two compartment model with a mean distribution half-life of 13.8 +/- 3.2 min and an elimination half-life of 70.0 +/- 16.0 min.,Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855840/),min,13.8,219681,DB00642,Pemetrexed
,16855840,elimination half-life,Pemetrexed disappearance from plasma was best described by a two compartment model with a mean distribution half-life of 13.8 +/- 3.2 min and an elimination half-life of 70.0 +/- 16.0 min.,Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855840/),min,70.0,219682,DB00642,Pemetrexed
,16855840,volume of distribution of,"The volume of distribution of and the clearance from the central compartment were 0.066 +/- 0.017 l/kg and 3.6 +/- 0.6 ml/min/kg, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855840/),[l] / [kg],0.066,219683,DB00642,Pemetrexed
,16855840,clearance from the central compartment,"The volume of distribution of and the clearance from the central compartment were 0.066 +/- 0.017 l/kg and 3.6 +/- 0.6 ml/min/kg, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855840/),[ml] / [kg·min],3.6,219684,DB00642,Pemetrexed
,16855840,Peak CSF concentrations,Peak CSF concentrations occurred 40-71 min after the start of the infusion with an average of 0.26 +/- 0.15 microM.,Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855840/),μM,0.26,219685,DB00642,Pemetrexed
,24989332,MTD,The MTD of SS1P was established as 45 mcg/kg.,"Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989332/),[mcg] / [kg],45,222694,DB00642,Pemetrexed
,22658814,MTD,"Therefore, the MTD for BI 2536 in combination with pemetrexed was 300 mg.",A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22658814/),mg,300,223182,DB00642,Pemetrexed
,23354655,time to progression,Median time to progression and survival was 2.7 and 7.3 months; PFS six was 22 %.,Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23354655/),month,2.7,232543,DB00642,Pemetrexed
,23354655,survival,Median time to progression and survival was 2.7 and 7.3 months; PFS six was 22 %.,Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23354655/),month,2.7,232544,DB00642,Pemetrexed
,23354655,survival,Median time to progression and survival was 2.7 and 7.3 months; PFS six was 22 %.,Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23354655/),month,7.3,232545,DB00642,Pemetrexed
,23963796,AUC,Pemetrexed (400-500 mg/m(2) IV) and carboplatin (AUC = 5 mg·min/ml IV) were administered q3w.,Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23963796/),[mg·min] / [ml],5,237840,DB00642,Pemetrexed
,23963796,AUC,The MTD on Schedule 2/1 was sunitinib 37.5 mg/day with pemetrexed 500 mg/m(2) and carboplatin AUC = 5 mg·min/ml; MTD on the CDD schedule was not established.,Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23963796/),[mg·min] / [ml],5,237841,DB00642,Pemetrexed
,23963796,MTD,"With this combination, in patients with advanced solid malignancies, sunitinib MTD on Schedule 2/1 was 37.5 mg/day.",Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23963796/),[mg] / [d],37.5,237842,DB00642,Pemetrexed
,31183244,flow rate,Chromatographic separation was achieved on a C18 column using a gradient mode containing water (containing 20 mM NaH2PO4 and 0.1% FA) and methanol at a flow rate of 0.8 mL/min.,Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[ml] / [min],0.8,238200,DB00642,Pemetrexed
,31183244,AUC(0-t),"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[mg] / [l·min],15747.12,238201,DB00642,Pemetrexed
,31183244,AUC(0-∞),"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[mg] / [l·min],12312.41,238202,DB00642,Pemetrexed
,31183244,AUC(0-∞),"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[mg] / [l·min],15976.18,238203,DB00642,Pemetrexed
,31183244,AUC(0-∞),"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[mg] / [l·min],12489.59,238204,DB00642,Pemetrexed
,31183244,MRT,"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[mg] / [l·min],12489.59,238205,DB00642,Pemetrexed
,31183244,MRT,"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),min,97.83,238206,DB00642,Pemetrexed
,31183244,MRT,"The AUC(0-t), AUC(0-∞), and MRT of gemcitabine decreased from 15747.12 ± 497.11 to 12312.41 ± 594.21 mg/L·min, 15976.18 ± 511.33 to 12489.59 ± 682.01 mg/L·min, and 97.83 ± 5.82 to 84.37 ± 2.79 min, respectively.",Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),min,84.37,238207,DB00642,Pemetrexed
,31183244,Cl,The Cl of gemcitabine increased from 0.019 ± 0.0067 to 0.024 ± 0.0013 L/min/kg.,Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[l] / [kg·min],0.019,238208,DB00642,Pemetrexed
,31183244,Cl,The Cl of gemcitabine increased from 0.019 ± 0.0067 to 0.024 ± 0.0013 L/min/kg.,Evaluation of the Effects of Astragalus membranaceus on the Pharmacokinetics of Pemetrexed Disodium and Gemcitabine in Rats by a Simple High-Performance Liquid Chromatography/UV Method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183244/),[l] / [kg·min],0.024,238209,DB00642,Pemetrexed
,20236726,area under the concentration-time curve (AUC),Patients received escalated doses of carboplatin area under the concentration-time curve (AUC) of 5 (cohort 1) or 6 (cohort 2) and pemetrexed 500 mg/m(2) every 3 weeks for six cycles.,Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20236726/),,5,243095,DB00642,Pemetrexed
,20236726,area under the concentration-time curve (AUC),Patients received escalated doses of carboplatin area under the concentration-time curve (AUC) of 5 (cohort 1) or 6 (cohort 2) and pemetrexed 500 mg/m(2) every 3 weeks for six cycles.,Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20236726/),,6,243096,DB00642,Pemetrexed
,20236726,overall response rate,"No complete responses and 12 partial responses were observed, giving an overall response rate of 60.0% [95% confidence interval (CI), 36.1-80.9%].",Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20236726/),%,60.0,243097,DB00642,Pemetrexed
,20236726,progression-free survival time,Median progression-free survival time for all patients was 7.6 months (95% CI: 4.8-8.0 months).,Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20236726/),month,7.6,243098,DB00642,Pemetrexed
,11505404,response rates,Phase II trials showed single-agent response rates of 16% and 23% in untreated patients with nonsmall cell lung carcinoma (NSCLC).,"Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505404/),%,16,245732,DB00642,Pemetrexed
,11505404,response rates,Phase II trials showed single-agent response rates of 16% and 23% in untreated patients with nonsmall cell lung carcinoma (NSCLC).,"Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505404/),%,23,245733,DB00642,Pemetrexed
,11505404,survival rate,"The median survival rate was 8.9 months (range, 1-15+ months).","Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505404/),month,8.9,245734,DB00642,Pemetrexed
,34052705,progression free survival (PFS),"Median progression free survival (PFS) was 4.5 months (95% CI 2.6 months-NA), with a 6-month and 12-month PFS rate of 38.5% (95% CI 19.3%-76.5%) and 25.6% (95% CI 8.9%-73.6%), respectively.","A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34052705/),month,4.5,252389,DB00642,Pemetrexed
,16322991,total systemic clearance,"Typical values of total systemic clearance, central volume of distribution, distributional clearance, and peripheral volume of distribution were 91.6 ml/min, 12.9 l, 14.4 ml/min, and 3.38 l, respectively.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),[ml] / [min],91.6,254215,DB00642,Pemetrexed
,16322991,central volume of distribution,"Typical values of total systemic clearance, central volume of distribution, distributional clearance, and peripheral volume of distribution were 91.6 ml/min, 12.9 l, 14.4 ml/min, and 3.38 l, respectively.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),l,12.9,254216,DB00642,Pemetrexed
,16322991,central volume of distribution,"Typical values of total systemic clearance, central volume of distribution, distributional clearance, and peripheral volume of distribution were 91.6 ml/min, 12.9 l, 14.4 ml/min, and 3.38 l, respectively.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),[ml] / [min],14.4,254217,DB00642,Pemetrexed
,16322991,distributional clearance,"Typical values of total systemic clearance, central volume of distribution, distributional clearance, and peripheral volume of distribution were 91.6 ml/min, 12.9 l, 14.4 ml/min, and 3.38 l, respectively.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),l,12.9,254218,DB00642,Pemetrexed
,16322991,distributional clearance,"Typical values of total systemic clearance, central volume of distribution, distributional clearance, and peripheral volume of distribution were 91.6 ml/min, 12.9 l, 14.4 ml/min, and 3.38 l, respectively.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),[ml] / [min],14.4,254219,DB00642,Pemetrexed
,16322991,peripheral volume of distribution,"Typical values of total systemic clearance, central volume of distribution, distributional clearance, and peripheral volume of distribution were 91.6 ml/min, 12.9 l, 14.4 ml/min, and 3.38 l, respectively.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),l,3.38,254220,DB00642,Pemetrexed
,16322991,terminal elimination half-life,"Based on these parameter estimates, the terminal elimination half-life of pemetrexed was approximately 3.5 h.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),h,3.5,254221,DB00642,Pemetrexed
,10501910,MTD,"The MTD of MTA was 600 mg/m(2), with neutropenia and thrombocytopenia, and cumulative fatigue as the dose-limiting toxicities.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),[mg] / [m],600,254279,DB00642,Pemetrexed
,10501910,half-life,"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),h,3.08,254280,DB00642,Pemetrexed
,10501910,maximum plasma concentration (Cpmax),"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),[μg] / [ml],137,254281,DB00642,Pemetrexed
,10501910,maximum plasma concentration (Cpmax),"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),[min·ml] / [m(2],40.0,254282,DB00642,Pemetrexed
,10501910,clearance (CL),"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),[μg] / [ml],137,254283,DB00642,Pemetrexed
,10501910,area under the curve (AUC),"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),[μg] / [ml],137,254284,DB00642,Pemetrexed
,10501910,area under the curve (AUC),"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),[min·ml] / [m(2],40.0,254285,DB00642,Pemetrexed
,10501910,apparent volume of distribution at steady state (Vdss),"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),μg,266,254286,DB00642,Pemetrexed
,28222073,area under the curve,Maximum tolerated dose for the combination was 240 mg per day oral rucaparib and carboplatin area under the curve 5 mg ml-1 min-1.,A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28222073/),[mg] / [min·ml],5,255887,DB00642,Pemetrexed
≈,28222073,half-life,"Oral rucaparib demonstrated dose-proportional kinetics, a long half-life (≈17 h), and good bioavailability (36%).",A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28222073/),h,17,255888,DB00642,Pemetrexed
,28222073,bioavailability,"Oral rucaparib demonstrated dose-proportional kinetics, a long half-life (≈17 h), and good bioavailability (36%).",A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28222073/),%,36,255889,DB00642,Pemetrexed
,32661922,zeta potential,"According to results, SA-PMX-Lips were spherical and the particle size was 219.7 ± 4.97 nm with a narrow polydispersity index (PDI) (0.231 ± 0.024) and a positive zeta potential 22.2 ± 0.52 mV.",Preparation and Evaluation of Stearylamine-Bearing Pemetrexed Disodium-Loaded Cationic Liposomes In Vitro and In Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32661922/),mv,22.2,258707,DB00642,Pemetrexed
,32661922,EE,Its EE was 92.39 ± 1.94% and DL was 9.15 ± 0.07%.,Preparation and Evaluation of Stearylamine-Bearing Pemetrexed Disodium-Loaded Cationic Liposomes In Vitro and In Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32661922/),%,92.39,258708,DB00642,Pemetrexed
,32661922,DL,Its EE was 92.39 ± 1.94% and DL was 9.15 ± 0.07%.,Preparation and Evaluation of Stearylamine-Bearing Pemetrexed Disodium-Loaded Cationic Liposomes In Vitro and In Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32661922/),%,9.15,258709,DB00642,Pemetrexed
,32661922,relative uptake rate (Re),"More notably, SA-PMX-Lips could improve the accumulation of drugs in the lungs and the relative uptake rate (Re) was 2.35 in the lungs, which indicated its lung targeting.",Preparation and Evaluation of Stearylamine-Bearing Pemetrexed Disodium-Loaded Cationic Liposomes In Vitro and In Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32661922/),,2.35,258710,DB00642,Pemetrexed
,30973978,clearance (CL),"The final population parameter estimates and relative standard error for clearance (CL) was 3.3 L/h (10.8), central volume of distribution (V1) was 5.2 L (7.8), peripheral volume of distribution (V2) was 5.9 L (14.5) and intercompartmental clearance (Q) was 6.8 L/h (14.3).",Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30973978/),[l] / [h],3.3,259276,DB00642,Pemetrexed
,30973978,central volume of distribution (V1),"The final population parameter estimates and relative standard error for clearance (CL) was 3.3 L/h (10.8), central volume of distribution (V1) was 5.2 L (7.8), peripheral volume of distribution (V2) was 5.9 L (14.5) and intercompartmental clearance (Q) was 6.8 L/h (14.3).",Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30973978/),l,5.2,259277,DB00642,Pemetrexed
,30973978,peripheral volume of distribution (V2),"The final population parameter estimates and relative standard error for clearance (CL) was 3.3 L/h (10.8), central volume of distribution (V1) was 5.2 L (7.8), peripheral volume of distribution (V2) was 5.9 L (14.5) and intercompartmental clearance (Q) was 6.8 L/h (14.3).",Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30973978/),l,5.9,259278,DB00642,Pemetrexed
,30973978,intercompartmental clearance (Q),"The final population parameter estimates and relative standard error for clearance (CL) was 3.3 L/h (10.8), central volume of distribution (V1) was 5.2 L (7.8), peripheral volume of distribution (V2) was 5.9 L (14.5) and intercompartmental clearance (Q) was 6.8 L/h (14.3).",Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30973978/),[l] / [h],6.8,259279,DB00642,Pemetrexed
,25037863,MTD,MTD of afatinib was 30 mg in SA and 50 mg in SB.,"A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25037863/),mg,30,266933,DB00642,Pemetrexed
,25037863,MTD,MTD of afatinib was 30 mg in SA and 50 mg in SB.,"A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25037863/),mg,50,266934,DB00642,Pemetrexed
,11021740,distribution,"The pharmacokinetics of pemetrexed disodium were best characterized by a two-compartment model with initial distribution and terminal elimination half-lives of 0.63 h and 2.73 h, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),h,0.63,269925,DB00642,Pemetrexed
,11021740,terminal elimination half-lives,"The pharmacokinetics of pemetrexed disodium were best characterized by a two-compartment model with initial distribution and terminal elimination half-lives of 0.63 h and 2.73 h, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),h,2.73,269926,DB00642,Pemetrexed
,11021740,central volume (V(c)),"Typical values of central volume (V(c)), distributional CL (Q), and peripheral volume (V(p)) were 11.3 1, 3.21 l/h, and 5.20 l, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),1,11.3,269927,DB00642,Pemetrexed
,11021740,distributional CL (Q),"Typical values of central volume (V(c)), distributional CL (Q), and peripheral volume (V(p)) were 11.3 1, 3.21 l/h, and 5.20 l, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),[l] / [h],3.21,269928,DB00642,Pemetrexed
,11021740,peripheral volume (V(p)),"Typical values of central volume (V(c)), distributional CL (Q), and peripheral volume (V(p)) were 11.3 1, 3.21 l/h, and 5.20 l, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),l,5.20,269929,DB00642,Pemetrexed
,21300929,PFS,"Median PFS in the ABT-751 arm was 2.3 months versus 1.9 for placebo (P = .819, log-rank) for the intention-to-treat population.",Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21300929/),month,2.3,270565,DB00642,Pemetrexed
,21300929,PFS,"Median PFS in the ABT-751 arm was 2.3 months versus 1.9 for placebo (P = .819, log-rank) for the intention-to-treat population.",Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21300929/),,1.9,270566,DB00642,Pemetrexed
,21107572,initial,"The distribution/elimination of pemetrexed in CSF was best described by a two-compartment model, with initial and terminal half-lives of 0.43 and 1.43 h, respectively.",Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107572/),h,0.43,271252,DB00642,Pemetrexed
,21107572,terminal half-lives,"The distribution/elimination of pemetrexed in CSF was best described by a two-compartment model, with initial and terminal half-lives of 0.43 and 1.43 h, respectively.",Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107572/),h,1.43,271253,DB00642,Pemetrexed
,21107572,maximal concentration,"The predicted maximal concentration in CSF was 588 μM, and high levels of pemetrexed appeared to be maintained for a long time.",Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107572/),μM,588,271254,DB00642,Pemetrexed
,21107572,Area under the curve,"Area under the curve and volume of distribution at steady state were 560 μM h and 1.14 ml, respectively.",Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107572/),h·μM,560,271255,DB00642,Pemetrexed
,21107572,volume of distribution at steady state,"Area under the curve and volume of distribution at steady state were 560 μM h and 1.14 ml, respectively.",Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107572/),ml,1.14,271256,DB00642,Pemetrexed
,28499946,zeta potential,LDC nanoparticles was found to have particle size 121.9±1.85nm and zeta potential -51.6mV±1.23 and entrapment efficiency 81.0±0.89%.,"Lipid drug conjugate nanoparticle as a potential nanocarrier for the oral delivery of pemetrexed diacid: Formulation design, characterization, ex vivo, and in vivo assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499946/),mv,51.6,273506,DB00642,Pemetrexed
,28499946,entrapment efficiency,LDC nanoparticles was found to have particle size 121.9±1.85nm and zeta potential -51.6mV±1.23 and entrapment efficiency 81.0±0.89%.,"Lipid drug conjugate nanoparticle as a potential nanocarrier for the oral delivery of pemetrexed diacid: Formulation design, characterization, ex vivo, and in vivo assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499946/),%,81.0,273507,DB00642,Pemetrexed
